What we found on the web about Tetrabenazine
Tetrabenazine is a drug for the symptomatical treatment of hyperkinetic movement disorder and is marketed under the trade names Nitoman in Canada and Xenazine in New Zealand and ...
It can be inhibited by reserpine and tetrabenazine. [1] VMAT is the main target of methamphetamine. By acting as a competitive antagonist, methamphetamine blocks the presynaptic cell's ...
Comes in 25mg scored tablets. Usual final dose in retrospective study cited below was 25-75mg/day, maximum dose during treatment was (average) 106mg/day.
DESCRIPTION: Tetrabenazine is a monoamine depletor for oral administration. The precise mechanism by which tetrabenazine exerts its anti-chorea effects is unknown, but is believed ...
Learn about the prescription medication Xenazine (Tetrabenazine Tablets), drug uses, dosage, side effects, drug interactions, warnings, and patient labeling.
OVATION Pharmaceuticals, Inc. has acquired from Prestwick Pharmaceuticals the exclusive license in the United States to commercialize Xenazine® (tetrabenazine).
You should not use this medication if you are allergic to tetrabenazine, or if you have severe or untreated depression, suicidal thoughts, liver disease, or past or present breast ...
XENAZINE® (Tetrabenazine) Approved by FDA for Patients with Chorea Associated with Huntington’s Disease. WASHINGTON, D.C., August 15, 2008 –Prestwick Pharmaceuticals, Inc., a ...
Tetrabenazine neither cures nor slows the disease — no drug yet has been shown to do that — but it's the most effective treatment for the uncontrolled movement called chorea ...
At HDDW we are so thankful to all who supported approval of tetrabenazine. We thank Prestwick for working diligently to get this drug to HD people, and for a planned patient ...
Here is what users have to say about Tetrabenazine

Tetrabenazine is a drug for the symptomatical treatment of hyperkinetic movement disorder and is marketed under the trade names Nitoman in Canada and Xenazine in New Zealand and some parts of Europe, and is also available in the USA as an orphan drug. On August 15, 2008 the U.S. Food and Drug Administration (FDA) approved the use of tetrabenazine to treat chorea associated with Huntington's disease (HD), the first in the US. The compound has been known since the 1950s.

Welcome to CWAnswers

CWAnswers is your guide to the sprawling world wide web. The directory aims to provide a useful guide made by users. You can share your knowledge as well - simply register and edit your first entry. For questions just contact the team at support - at - cwanswers.com.

Weblinks

Top 10

Things you find nowhere else.

Comments

You must be logged in to post a comment.

No comments yet on this topic. Be the first one!